Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.Res. 1125

ResolutionFederalHouseIn Committee
Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.
About This Bill
Committee
Latest Action · September 18, 2020
Referred to the House Committee on Energy and Commerce.
Congress
116th (2019–2021)
Introduced
September 18, 2020
Cosponsors (22)
22D 0R
View PDF ↗

Summary

Highlight any text to annotate
This resolution expresses the sense of the House of Representatives that federal agencies should take appropriate actions to (1) ensure meaningful engagement of communities of color in the conduct of COVID-19 (i.e., coronavirus disease 2019) research and participation in clinical trials, and (2) improve equitable access to safe and effective vaccines.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.